Seung Eun Choi, S-Alpha Therapeutics - Slowing the Progress of Pediatric Myopia | LSI USA '24

Seung Eun Choi  0:04  
It's great honor for me to tell you about SR file therapeutics story, which has been through Since 2019 when the company has been established. My name is Seung Eun Choi, CEO and founder of the company. And let me tell you about srfs therapeutics. Mission is to be a leader of digital health based on convergence of it and bio. And let's talk about problem. First, there are medical needs in the world, as we know, to healthcare professionals, futures, poor treatment could be medical men needs and to industries. The high price of development, of neutral could be burdened to government, increasing health economy could be and to patients, most of all, low satisfaction to treatment. Considering price could be medical amendments, our company is trying to our best to deliver more impact for new technology with medical digital solution for overcoming established treatment in healthcare area. Let's talk about core technology based. The core technology is based on convergence between information technology and biotechnology. It means that our core technology will start from medical theoretical background, which can be searched in form of original article or review article, and the medical background theoretical background will be evaluated if the background research article could be Translated into digital program or not once the distal program could be decisible. Software could be engineered and for deliver the treatment intervention to users, and efficacy and safety of the software could be evaluated in form of clinical trials, let me say about the clinical or software engineering in detail. It is called the CIDP model. C is calibration of C, A is activity. Data is a way, and D is from data analysis, and P is from personalization mechanics, including artificial intelligence. From the models we have several pipelines could be delivered to several diverse market for prescription digital therapies. There is SA disaster one and 003, and 008, heavy version and 014, as you know, software has really, really big flexibility for making pipeline. The other one is with the intention of slowing the progress of pediatric myopia. Gen 03 is for cancer. Cache eight, heavy version is software as a medical device for enhancing general immunity. And 0144 PTSD in the wireless market, we have SAA digital eight lite version. And also we are manufacturing SAA digital one shame device as A, B to C, gamification software. And let me introduce about 001. Is a leading pipeline of our company, software for slowing progress of pediatric my PR. The software was engineered in this environment of qualified management system. It is certified with ISO as well as Korean CRP, the software is granted as innovative medical device in South Korea. The efficacy of website is as a one, as a software as a medical device. We are doing several clinical trials in the world. In United States, we are doing feasibility study and for Provo concept data we published, we presented the six month treatment effect in terms of proof of concept in OIS circle, and one year's treatment effect will be presented in 2000 to 20 to 24 hours. It will be held in theater coming May. And the people test study is on the track in South Korea. Let's show you the distal program like this. It is adjusted for considering target population, because target population is very young. And we also will deliver the clinical measure, because doctors will watch the. A clinical measure with change of axial length and change of cycle reflection during treatment period. And let us see the population of myopia. The population of myopia is about 30% in 2020 but it will be estimated to increase about 50% of the whole population in the world in 2050 and the prevalence of myopia will be occupied about 50% by pediatric myopia too. And let's talk about core pipeline two in in the company. It is called as a simu. The The asimu is a light version of a state as a it. The software is engineered in the environment of quality management. This year stamp two, and it is the star device where to eat the public watch or me bend like wellness, for really measuring heart rate. And it is determined as well, is in global market, and it is ready to be launched. And the modern name is sa disager A, considering provable concept data we published in the genre. And based on the data, saa disager A can elevate Hi neutralizing antibody against influenza virus type p when it is used with parallely, coincidentally with influenza vaccination, we surveyed 1000 page others if they have a willingness to Use the mobile application in case that it has some function to enhance immunity, about 50% of the subway others are saying yes, let's say about the company's status regarding funding and the State. The status is early funding stage after Series B with the planned investment. The Milestone is planned like as the company will do Completion of people touch trials for SDHD as a one as a software as a medical device for slowing progress of pediatric myopia in South Korea. It will be referenced in several countries globally. And also our company will do completion of a feasibility study for SDH 01 in United States, which will be rolling stone of global market entrance two. And also we are ready to launch the SMU in global market too. Let me introduce our 45 members, all experts, almost experts in R and D area, as well as being business strategies and operations. We have six members of BOD. And I am surgeon, and I used to be a pediatric surgeon and immunologist, and I have some experience, more than 10 years in Industry field. There are so other beauty members, has long experience in their specific specialty, and we are working with Global Advisors and contributors for special pipeline, and we are very proud of global top tier, leading investors too. Please listen me, if you have any interest to be any type of partners with SRF authorities. Thank you. Applause.